Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
Checkpoint Therapeutics, Inc. (CKPT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"[SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT CHECKPOINT THERAPEUTICS, INC. Warrant Shares: [_______] Issue Date:______, 2023 Initial Exercise Date:______, 2023 THIS [SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. and on or prior to 5:00 p.m. on [______________] 1 2 but not thereafter, to subscribe for and purchase from Checkpoint Therapeutics, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Sect...",
"Form of Placement Agent Warrant",
"Form of Inducement Letter Agreement, by and between Checkpoint Therapeutics, Inc. and the Holder",
"Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds" |
|
| 09/26/2023 |
SC 13D/A
| Fortress Biotech, Inc. reports a 11.3% stake in CHECKPOINT THERAPEUTICS, INC. |
| 09/26/2023 |
4
| Fortress Biotech, Inc. (10% Owner) has filed a Form 4 on Checkpoint Therapeutics, Inc.|
Txns:
| Granted 80,906 shares
@ $0 |
|
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/31/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/27/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/06/2023 |
SC 13D/A
| Fortress Biotech, Inc. reports a 13.6% stake in CHECKPOINT THERAPEUTICS, INC. |
| 07/03/2023 |
4
| Fortress Biotech, Inc. (10% Owner) has filed a Form 4 on Checkpoint Therapeutics, Inc.|
Txns:
| Granted 81,406 shares
@ $0 |
|
| 06/15/2023 |
4
| WEISS MICHAEL S (Director) has filed a Form 4 on Checkpoint Therapeutics, Inc.|
Txns:
| Granted 17,483 shares
@ $0 |
|
| 06/15/2023 |
4
| SALZMAN BARRY M (Director) has filed a Form 4 on Checkpoint Therapeutics, Inc.|
Txns:
| Granted 17,483 shares
@ $0 |
|
| 06/15/2023 |
4
| ROSENWALD LINDSAY A MD (Director) has filed a Form 4 on Checkpoint Therapeutics, Inc.|
Txns:
| Granted 17,483 shares
@ $0 |
|
| 06/15/2023 |
4
| Herskowitz Neil (Director) has filed a Form 4 on Checkpoint Therapeutics, Inc.|
Txns:
| Granted 17,483 shares
@ $0 |
|
| 06/15/2023 |
4
| Boilen Scott (Director) has filed a Form 4 on Checkpoint Therapeutics, Inc.|
Txns:
| Granted 17,483 shares
@ $0 |
|
| 06/15/2023 |
4
| Bechon Christian (Director) has filed a Form 4 on Checkpoint Therapeutics, Inc.|
Txns:
| Granted 17,483 shares
@ $0 |
|
| 06/13/2023 |
8-K
| Appointed a new director |
| 05/24/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"  PRE-FUNDED COMMON STOCK PURCHASE WARRANT   Checkpoint Therapeutics, Inc.   Warrant Shares: [_______] Issue Date:______, 2023       Initial Exercise Date: _______, 2023   THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Checkpoint Therapeutics, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as d...",
"  [SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT   CHECKPOINT THERAPEUTICS, INC.   Warrant Shares: [_______] Issue Date:______, 2023       Initial Exercise Date: ______, 2023   THIS [SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m.  on [______________] 1 2 but not thereafter, to subscribe for and purchase from Checkpoint Therapeutics, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant sha...",
"  PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT   CHECKPOINT THERAPEUTICS, INC.   Warrant Shares: [_______] Issue Date: May 25, 2023       Initial Exercise Date: May 25, 2023   THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m.  on May 23, 2028 but not thereafter, to subscribe for and purchase from Checkpoint Therapeutics, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall ...",
"Opinion of Alston & Bird LLP",
"SECURITIES PURCHASE AGREEMENT   This Securities Purchase Agreement is dated as of May 23, 2023, between Checkpoint Therapeutics, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto .   WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.   NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are...",
"Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules" |
|
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/21/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/19/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/14/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 04/04/2023 |
4
| Oliviero James F III (CEO, President and Director) has filed a Form 4 on Checkpoint Therapeutics, Inc.|
Txns:
| Granted 250,000 shares
@ $0 |
|
| 04/04/2023 |
4
| GRAY WILLIAM GARRETT (CFO) has filed a Form 4 on Checkpoint Therapeutics, Inc.|
Txns:
| Granted 100,000 shares
@ $0 |
|
| 04/04/2023 |
4
| Fortress Biotech, Inc. (10% Owner) has filed a Form 4 on Checkpoint Therapeutics, Inc.|
Txns:
| Granted 35,714 shares
@ $0
Granted 42,500 shares
@ $0 |
|
| 04/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"[SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT CHECKPOINT THERAPEUTICS, INC. Warrant Shares: [_______] Issue Date:______, 2023 Initial Exercise Date: _______, 2023 THIS [SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on [______________] 1 2 but not thereafter, to subscribe for and purchase from Checkpoint Therapeutics, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . &#...",
"PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT CHECKPOINT THERAPEUTICS, INC. Warrant Shares: [_______] Issue Date: April 4, 2023 Initial Exercise Date: April 4, 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on March 30, 2028 but not thereafter, to subscribe for and purchase from Checkpoint Therapeutics, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant is issued pursuant ...",
"Letter re: Securities Registered under Registration Statement on Form S-3",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of March 30, 2023, between Checkpoint Therapeutics, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares and/or pursuant to an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and Rule 506 promulgated thereunder as to the Private Placement Warrants , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agr...",
"Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules" |
|
| 04/04/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/31/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
|
|
|